Traders will likely watch international headlines Friday after the major events of the week have left stocks in a holding pattern.
U.S. stocks closed mostly lower Thursday as modest gains in financial stocks failed to offset declines in health care and utilities stocks.
Biogen shares are fully valued following the spinoff of its hemophilia business, Morgan Stanley argues.
Promising new research suggests that marijuana could be used to treat Alzheimer's, but there's a major roadblock: the federal government.
South Korea's Samsung Bioepis has won a high-stakes court case against U.S. drug firm AbbVie.
The hire signals Carl Icahn may be back, at a time when biotech valuations are 25 percent off their 2015 highs.
CNBC's Meg Tirrell speaks with John Cox, Bioverativ CEO, about the company's spinoff from Biogen, its new innovations in treating hemophilia.
Citi Research says shares of Biogen could rally 15 percent in the next 12 months on the launch of Spinraza.
U.S. stock index futures pointed to a mixed open after the Dow closed above 20,000 points for the first time in the previous session.
Some of the names on the move ahead of the open.
The Dow burst through 20,000 after just a two-month, 1000-point ride, and strategists say stocks could continue to move up for now, as retail investors are lured in.
Here's why the congressman's Cabinet nomination has raised flags for ethics experts, Vox reports.
Morgan Stanley on Friday told clients of a group of stocks that could rally on earnings.
Discussing next week's earnings including McDonald's, Qualcomm and more. With CNBC's Melissa Lee and the Options Action traders.
Donald Trump's pick for secretary of HHS will be in the hot seat when he goes before the Senate on Wednesday.
Buying the biotech ETF during JPMorgan's annual health-care conference has proven to be a profitable trade, research shows.
The "Fast Money" traders weigh in on the health care sector, as the Trump administration attempts to repeal Obamacare.
CNBC's Meg Tirrell reports the latest on the war on drug prices as several drugs are seeing their prices hiked since the start of the year.
CNBC's Meg Tirrell reports that one analyst is raising a red flag on Biogen due to the incredibly high price of a new drug to treat a rare genetic disease in children.
Ronny Gal, Sanford C. Bernstein analyst, shares his expectations on the biotech sector in 2017.